MDGL NASDAQ
Credit Risk of going bust: lower than 79% of companies Debt: 3.3% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $1.39 (down 99.7%), Madrigal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $347.8M against a stock market value of $10.11B.
Distance to default 9.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $171.4M (short-term plus half of long-term), stock volatility 43.5%; Altman Z'' -2.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
West Conshohocken, PA 19428
US
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-Ã agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sibold William John | S-Sale | 60 | $533.09 | 2026-09-11 |
| Sibold William John | S-Sale | 106 | $534.06 | 2026-09-11 |
| Sibold William John | S-Sale | 218 | $535.94 | 2026-09-11 |
| Sibold William John | S-Sale | 160 | $537.62 | 2026-09-11 |
| Sibold William John | S-Sale | 687 | $540.59 | 2026-09-11 |